Harrow Business Model Canvas

Originators and developers provide assets for in-licensing or acquisition, enabling Harrow to access late-stage branded and generic ophthalmics. Partnerships accelerate portfolio expansion across branded and generic products, targeting a U.S. ophthalmic Rx market of roughly $15B and indications like dry eye (≈16M), AMD (≈2.1M) and glaucoma (≈3M). Deal structures commonly balance upfronts ($1M–$50M), milestone pools ($5M–$200M) and royalties (5–25%), aligning risk and return to unmet U.S. eye care needs.

Strategic suppliers, CMOs, originators, KOLs, distributors and PBMs secure supply, speed launches and drive access while aligning economics via deals and data-sharing. Dual sourcing, long-term contracts and technical alliances reduce risk and COGS variability. Commercial partners (distributors/PBMs) enable nationwide reach and formulary access.

Preparation and submission of NDAs/ANDAs and supplements is core, with FDA review timelines in 2024 remaining 10 months for standard and 6 months for priority reviews. Ongoing communication with regulators keeps alignment on data and labeling. Robust pharmacovigilance and quality systems meet global reporting obligations. Label updates are issued promptly to reflect new data and safety signals.

Harrow scaled asset scouting in 2024, screening 100+ candidates and closing multiple licenses with typical diligence spend >$1M per asset. Drug development timelines ~10 years and ~$1B; FDA reviews 10m standard/6m priority (2024). Supply-chain controls (serialization, cold‑chain) and commercialization efforts target the $38.5B ophthalmics market (2024).

Experienced ophthalmology teams guide product development and clinician education, aligning clinical protocols with real-world practice. Medical affairs drives peer-reviewed evidence dissemination and KOL engagement to support adoption. Dedicated safety teams run active surveillance and rapid adverse event response. Clinical insights feed strategy, shaping messaging, trial design and market positioning.

Harrow's key resources combine a diversified ophthalmic portfolio with NDAs/ANDAs, clinical teams and CMO partnerships, driving recurring revenue and pipeline-led growth. Financial strength and deal-making capacity support M&A and scale. Redundant suppliers and quality systems secure supply continuity.

Strict FDA cGMP, EMA and USP <71> ophthalmic sterility standards protect patients; WHO estimates about 10% of medicines in low- and middle-income countries are substandard or falsified, underscoring risk. Consistent performance reduces adverse events and liability; transparent quality practices build stakeholder confidence, while robust QA programs cut recall-related shortages and supply disruptions.

Harrow delivers ophthalmic-specific products into a $50.6B global market (2024), combining clinician-trusted ocular expertise, strict cGMP/FDA/EMA sterility compliance and reliable supply to cut recalls and liability. Competitive pricing, generics access (≈90% U.S. Rx by volume, 2024) and patient support raise initiation and adherence (+18% real-world, 2024).

Continuing education and webinars deliver best-practice updates, supported by a 2024 global corporate e-learning market estimated at about $400 billion, showing strong demand for scalable learning. Procedure support and in-service training reduce operational errors and aid staff retention. Onboarding materials simplify new-product adoption and cut ramp-up time. Outcomes evidence from post-training metrics underpins content and ROI reporting.

Reps/MSLs deliver real‑world data and peer programs to 20M annual cataract surgeons (2024), driving loyalty; account teams target 99% fill‑rate and transparent institutional pricing; education leverages a $400B e‑learning market (2024) to cut ramp time; patient programs raise adherence ~20% and reduce OOP via copay/PAPs; 24/7 channels meet 24‑hour SLA for safety and risk insights.

Presence in eRx systems simplifies provider choice, with 2024 data showing over 90% of US ambulatory providers using eRx-enabled EHRs. Formularies and standardized order sets embedded in workflows steer selection toward preferred products. Built-in prior authorization support reduces administrative delays and denials. Tight EMR integration improves medication adherence through streamlined prescribing and follow-up.

Omnichannel distribution reaches ~95% of UK pharmacies and 90%+ US ambulatory eRx users in 2024, with 24–48h logistics and 95–98% OTIF service. Direct hospital contracts, consignment and EDI cut transaction costs 40–60% and reduce stockouts ~30%. Digital channels became primary lead source, boosting demo-to-trial conversion to ~20–30%.

Hospitals and ambulatory surgery centers operate the majority of surgical and acute ophthalmic care, with about 3.7 million US cataract procedures in 2024 and roughly 70% performed in outpatient settings. They prioritize supply assurance, transparent pricing, and clinical quality metrics. These customers favor value contracting and inventory/consignment solutions to reduce cost and stockouts. Strict regulatory compliance and sterile integrity requirements drive procurement and service specifications.

Ophthalmologists (≈19,000) drive clinical adoption and need strong evidence and on-site support. Optometrists deliver frontline care (England ≈16M sight tests/year) and value affordability and concise education. Hospitals/ASCs (≈3.7M US cataracts 2024) and pharmacies (≈4.5B US scripts 2024) prioritize supply, pricing and outcomes; PBMs (top‑3 ≈80%) shape access and net price (~30% rebates).

Upfront payments secure rights to assets and provide immediate capital; in licensing deals upfronts often represent a significant portion of total consideration. Sales-based royalties directly reduce gross margin by the royalty rate, commonly ranging from 5 to 25 percent. Milestones tie costs to development or commercialization progress, shifting risk from upfront spend to achievement-based payments. Deal structure—mix of upfront, milestones, royalties—dictates cash flow timing and risk allocation.

CMO, materials & packaging drove ~60–70% of unit COGS (2024); sterility/testing added 10–20% while scale cut COGS 15–30%. Dev costs: Formulation $1–5M, Phase II $20–60M, Phase III $100–400M (2024). Commercial spend: rep ~$140k, MSL ~$180k, payer rebates 20–30% (2024).

Agreements with hospitals and ASCs deliver the bulk of procedure volumes, with 2024 contracts projected to drive approximately 68% of predictable throughput. Tiered pricing and rebate structures align incentives, reducing unit costs as volumes scale. Bundled offerings map to procedure workflows to streamline OR and ASC logistics. Performance clauses (fill rates, on-time delivery) stabilize supply and mitigate stockouts.

Branded prescriptions drive core sales; ASP premium ~15% vs generics; 2024 global ophthalmic market ~33.4B USD.

Generics and hospital/ASC contracts supply volume; hospital contracts ~68% throughput; payer/distributor discounts 10–25%.

Licensing/upfronts $5M–$50M+ (2024), royalties 5–12%, plus co-promotion fees and recurring medical education revenue.